Phibro Animal Health Corporation
PAHC · NASDAQ Global Market · USD
34,64USD
+0,03 (+0,09 %)Stand 10. Nov., 21:00
Nachbörslich34,640,00 (0,00 %)19:30 ET
Kennzahlen
- Eröffnung
- 34,48
- Vortag
- 34,61
- Tagesspanne
- 34,10 – 35,24
- 52 Wochen
- 28,25 – 60,08
- Volumen
- 223.790
- Ø Volumen
- 232.335
- Börsenwert
- 1,41 Mrd. $
- KGV
- 13,6
- Gewinn je Aktie (TTM)
- 2,51
- Dividendenrendite
- 1,4 %
- Beta
- 0,4
- Nächste Zahlen
- 3. Feb. 2027
Finanzen
| USD | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Umsatz | 1,52 Mrd. | 1,3 Mrd. | 1,02 Mrd. | 977,89 Mio. | 942,26 Mio. |
| Herstellungskosten | 1,01 Mrd. | 896,27 Mio. | 704,59 Mio. | 679,65 Mio. | 656,86 Mio. |
| Bruttogewinn | 511,71 Mio. | 399,94 Mio. | 313,09 Mio. | 298,24 Mio. | 285,4 Mio. |
| Forschung und Entwicklung | 0 | 0 | 0 | 0 | 0 |
| Vertrieb und Verwaltung | 312,5 Mio. | 289,48 Mio. | 259,78 Mio. | 226,39 Mio. | 206,41 Mio. |
| Operatives Ergebnis | 198,44 Mio. | 110,47 Mio. | 53,32 Mio. | 71,85 Mio. | 78,99 Mio. |
| EBITDA | 236,46 Mio. | 146,85 Mio. | 69,06 Mio. | 106,03 Mio. | 117,13 Mio. |
| Nettogewinn | 99,72 Mio. | 48,26 Mio. | 2,42 Mio. | 32,61 Mio. | 49,18 Mio. |
| Gewinn je Aktie (verwässert) | 2,44 | 1,19 | 0,06 | 0,81 | 1,21 |
Umsatz nach Segment
Produkte · FY 2026
- Vaccines156,42 Mio. $100,00 %+14,05 %
Anteil · ggü. Vorjahr (FY 2025)
Regionen · FY 2026
- UNITED STATES877,13 Mio. $57,78 %+18,54 %
- Latin America and Canada340,67 Mio. $22,44 %+14,07 %
- EMEA187,94 Mio. $12,38 %+17,29 %
- Asia Pacific112,36 Mio. $7,40 %+15,34 %
Anteil · ggü. Vorjahr (FY 2025)
Bewertung
Letzte 12 Monate
- KGV
- 13,6
- Kurs-Umsatz-Verhältnis
- 0,9
- Kurs-Buchwert-Verhältnis
- 3,4
- PEG
- 0,3
- Bruttomarge
- 33,8 %
- Operative Marge
- 13,0 %
- Nettomarge
- 6,7 %
- Verschuldungsgrad
- 1,9
- EV/EBITDA
- 8,9
- Eigenkapitalrendite
- 27,4 %
- Kapitalrendite (ROIC)
- 11,7 %
- Free-Cashflow-Rendite
- 1,5 %
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|---|
| Bruttomarge | 33,7 % | 30,9 % | 30,8 % | 30,5 % | 30,3 % |
| Operative Marge | 13,1 % | 8,5 % | 5,2 % | 7,3 % | 8,4 % |
| Nettomarge | 6,6 % | 3,7 % | 0,2 % | 3,3 % | 5,2 % |
| KGV | 12,8 | 21,5 | 284,0 | 16,9 | 15,8 |
| Kurs-Umsatz-Verhältnis | 0,8 | 0,8 | 0,7 | 0,6 | 0,8 |
| Kurs-Buchwert-Verhältnis | 3,3 | 3,6 | 2,7 | 2,0 | 3,0 |
| Verschuldungsgrad | 2,0 | 2,7 | 2,0 | 1,8 | 1,8 |
| Liquidität 3. Grades | 3,0 | 2,8 | 2,9 | 3,3 | 3,0 |
| Dividendenrendite | 1,5 % | 1,9 % | 2,8 % | 3,5 % | 2,5 % |
| Unternehmenswert | 2 Mrd. | 1,73 Mrd. | 1,15 Mrd. | 1,02 Mrd. | 1,17 Mrd. |
| EV/EBITDA | 8,5 | 11,8 | 16,6 | 9,7 | 10,0 |
| Eigenkapitalrendite | 25,9 % | 16,9 % | 0,9 % | 11,5 % | 18,7 % |
| Kapitalrendite (ROIC) | 11,8 % | 7,2 % | 1,4 % | 5,3 % | 7,0 % |
| Free-Cashflow-Rendite | 0,8 % | 4,0 % | 6,7 % | −6,9 % | −0,7 % |
Wachstum
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|---|
| Umsatz | +17,1 % | +27,4 % | +4,1 % | +3,8 % | +13,1 % |
| Bruttogewinn | +27,9 % | +27,7 % | +5,0 % | +4,5 % | +5,2 % |
| Operatives Ergebnis | +79,6 % | +107,2 % | −25,8 % | −9,0 % | +5,5 % |
| Nettogewinn | +106,6 % | +1.897,7 % | −92,6 % | −33,7 % | −9,6 % |
| Gewinn je Aktie | +105,0 % | +1.883,3 % | −92,6 % | −33,1 % | −9,7 % |
| Freier Cashflow | −76,4 % | −9,8 % | +220,5 % | −613,3 % | −128,4 % |
| Dividende je Aktie | −0,2 % | +0,0 % | 0,0 % | −0,0 % | +0,1 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 6Kaufen
- 4Halten
- 4Verkaufen
- 0Stark verkaufen
Kursziel
28,00
Durchschnitt · −19,17 %
Schätzungen
| FY 2027 | FY 2028 | FY 2029 | |
|---|---|---|---|
| Umsatz (Ø) | 1,58 Mrd. | 1,63 Mrd. | 1,68 Mrd. |
| Umsatz (Tief – Hoch) | 1,57 Mrd. – 1,59 Mrd. | 1,62 Mrd. – 1,65 Mrd. | 1,68 Mrd. – 1,68 Mrd. |
| Gewinn je Aktie (Ø) | 3,49 | 3,86 | 4,15 |
| Gewinn je Aktie (Tief – Hoch) | 3,47 – 3,51 | 3,68 – 4,12 | 4,12 – 4,19 |
| Analysten | 2 | 2 | 1 |
Letzte Änderungen
- Citigroup14. Mai 2026Neutral
- JP Morgan7. Nov. 2025Overweight
- B of A Securities29. Aug. 2025Underperform
- JP Morgan7. Juli 2025Neutral → Overweight
- Morgan Stanley25. Juni 2025Equal Weight
- Morgan Stanley8. Mai 2025Equal Weight
- Barclays10. Feb. 2025Underweight
- Morgan Stanley17. Dez. 2024Equal Weight
Quartalszahlen
Nächste Zahlen: 3. Feb. 2027| Nov. 2026 | Aug. 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 0,78 | 0,71 | 0,72 | 0,69 | 0,59 | 0,52 | 0,52 | 0,40 |
| Gewinn je Aktie · Tatsächlich | 0,79 | 0,85 | 0,76 | 0,87 | 0,73 | 0,57 | 0,63 | 0,54 |
| Abweichung | +0,89 % | +19,21 % | +5,56 % | +26,09 % | +23,73 % | +9,62 % | +21,15 % | +35,00 % |
| Umsatz · Tatsächlich | 386,8 Mio. | 396,7 Mio. | 383,5 Mio. | 373,9 Mio. | 363,9 Mio. | 378,7 Mio. | 347,8 Mio. | 309,3 Mio. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 25. Nov. 2026 | 16. Dez. 2026 | 0,12 |
| 2. Sept. 2026 | 23. Sept. 2026 | 0,12 |
| 3. Juni 2026 | 24. Juni 2026 | 0,12 |
| 4. März 2026 | 25. März 2026 | 0,12 |
| 26. Nov. 2025 | 17. Dez. 2025 | 0,12 |
| 3. Sept. 2025 | 24. Sept. 2025 | 0,12 |
| 4. Juni 2025 | 25. Juni 2025 | 0,12 |
| 5. März 2025 | 26. März 2025 | 0,12 |
| 27. Nov. 2024 | 18. Dez. 2024 | 0,12 |
| 4. Sept. 2024 | 25. Sept. 2024 | 0,12 |
| 5. Juni 2024 | 26. Juni 2024 | 0,12 |
| 5. März 2024 | 27. März 2024 | 0,12 |
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 52,40 %
- Investoren mit 13F-Meldung
- 215
Größte Investoren
- BLACKROCK, INC.7,93 %3,22 Mio.
- FMR LLC7,78 %3,16 Mio.
- STATE STREET CORP2,56 %1,04 Mio.
- MILLENNIUM MANAGEMENT LLC2,31 %936.701
- VANGUARD CAPITAL MANAGEMENT LLC2,27 %923.318
- GEODE CAPITAL MANAGEMENT, LLC1,62 %657.350
- LORD, ABBETT & CO. LLC1,61 %653.305
- DIMENSIONAL FUND ADVISORS LP1,31 %531.087
Insider-Geschäfte
- David Glenn6. Aug. 2026 · officer: Chief Financial OfficerKauf3482 Aktien
- Miller Larry Lee6. Aug. 2026 · officer: Chief Operating OfficerKauf3726 Aktien
- Rodriguez Patrick6. Aug. 2026 · officer: VP Finance and TreasurerKauf1503 Aktien
- David Glenn6. Aug. 2026 · officer: Chief Financial OfficerKauf3334 Aktien
- Miller Larry Lee6. Aug. 2026 · officer: Chief Operating OfficerKauf3522 Aktien
- BENDHEIM Jonathan6. Aug. 2026 · directorKauf2716 Aktien
- Weinstein Judith6. Aug. 2026 · officer: See RemarksKauf2478 Aktien
- BENDHEIM JACK6. Aug. 2026 · director, 10 percent owner, officer: Executive ChairmanKauf12.103 Aktien
Vergleichbare Unternehmen
Über das Unternehmen
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
Führung
- Jack Clifford BendheimExecutive Chairman
- Larry L. MillerChief Operating Officer
- Glenn C. DavidChief Financial Officer
- Daniel BendheimCEO, President & Director
- Judith A. WeinsteinSenior Vice President, General Counsel & Corporate Secretary
- Jonathan BendheimExecutive VP of Talent, Technology and Business Development & Director
- CEO
- Daniel Bendheim
- Mitarbeitende
- 2.605
- Hauptsitz
- Teaneck, NJ, US
- Sektor
- Healthcare
- Branche
- Drug Manufacturers - Specialty & Generic
- Börsengang
- 11. Apr. 2014
- Website
- pahc.com
Nachrichten
- Seeking Alpha · 7. Nov., 0:24Phibro Animal Health Corporation (PAHC) Q1 2027 Earnings Call Transcript
- Zacks Investment Research · 4. Nov., 21:31Phibro (PAHC) Reports Q1 Earnings: What Key Metrics Have to Say
- Business Wire · 4. Nov., 16:22Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance
- Business Wire · 3. Nov., 16:10Phibro Animal Health Corporation Declares Quarterly Dividend
- Business Wire · 28. Okt., 16:30Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
- Zacks Investment Research · 23. Okt., 13:10Will Phibro (PAHC) Beat Estimates Again in Its Next Earnings Report?
- Zacks Investment Research · 21. Okt., 12:41PAHC or SYK: Which Is the Better Value Stock Right Now?
- Zacks Investment Research · 5. Okt., 12:40PAHC vs. HAE: Which Stock Is the Better Value Option?
- Defense World · 1. Okt., 6:15Head-To-Head Survey: Tvardi Therapeutics (NASDAQ:TVRD) versus Phibro Animal Health (NASDAQ:PAHC)
- Zacks Investment Research · 21. Sept., 11:01Best Momentum Stocks to Buy for September 21st
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.